Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice

Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice

Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid change, glucose homeost...

Full description

Bibliographic Details
Main Authors: Geng-Ruei Chang, Po-Hsun Hou, Wei-Cheng Yang, Chao-Min Wang, Pei-Shan Fan, Huei-Jyuan Liao, To-Pang Chen
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Pharmaceuticals
Subjects:
doxepin
obesity
chromium
fatty liver disease
renal impairment
glucose intolerance
Online Access:https://www.mdpi.com/1424-8247/14/3/267

Similar Items

Similar Items